Clinical trials: Pediatric Cancers
Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Acute Myeloid Leukemia in Children, Myeloproliferative Neoplasm
- Trial name
- NCT06421155
- Testing
- MRF with neurocognative studies
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase.
- Trial name
- NCT03817398
- Testing
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment
- Where
- 173 sites in United States, Australia and 2 more
- Volunteers
- 110 people
- Sponsor
- Children's Oncology Group
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
These laboratory trial studies the development and treatment of a mouse model for acute myeloid leukemia (AML) using samples from younger patients with AML.
- Trial name
- NCT01576185
- Testing
- laboratory biomarker analysis, quizartinib, sorafenib tosylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Palliative Medicine, Pediatric ALL
Paediatric Palliative Care Pain Management in the Community
To describe the the barriers and facilitators experienced by carers and healthcare professionals when managing medicines for pain relief for infants, children, and young people approaching the end of life in out of hospital…
- Trial name
- PARAMOUNT (NCT04519632)
- Testing
- Qualitative study
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Postoperative Pain
Rectal Dexmedetomidine Niosomes for Postoperative Analgesia in Pediatric Cancer Patients.
Applying nanotechnology in drug delivery systems improved the bioavailability and kinetic profile of drugs in biological systems
- Trial name
- DEX-NANO (NCT05340725)
- Testing
- DEX-IV, DEX-Rectal, DEX-Nano-Rectal
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Assiut University
Oncology, Trauma
The Impact of Chemotherapy on Memory Function and the Development of Traumatic Symptoms in Children With Cancer
Background: While treatment for pediatric cancer has improved significantly over the past 40 years, the neurotoxic side-effects of the chemotherapy agents themselves are now being recognized.
- Conditions
- Oncology, Trauma, Pediatric
- Trial name
- NCT01108952
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Lymphatic Malformations
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
- Trial name
- EPIK-L1 (NCT05948943)
- Testing
- Alpelisib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Pediatric Cancer, Solid Tumor Pediatric
Durvalumab and Tremelimumab for Pediatric Malignancies
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the…
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Trial name
- NCT03837899
- Testing
- Durvalumab / Tremelimumab Combination Therapy
- Where
- 19 sites in United States, France and 5 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Pediatric Oncology
The Experience of the Child With Cancer When Port à Cath Needle : Child's Speech
This qualitative research refers to the descriptive phenomenological method of Hurssel which allows an analysis of the experience and an understanding of the phenomenon.
- Trial name
- ELEAPort (NCT05691816)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Clermont-Ferrand
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Pediatric ALL
Reducing Fasting Time in Children for Sedation
Patients are asked to be fasted for certain period of time before sedation to reduce the risk of pulmonary aspiration. However, fasting can be harmful, especially in children who has smaller reserves of energy and fluids compared…
- Trial name
- NCT05757882
- Testing
- 4 hours of fasting time, 2 hours of fasting time
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Eunah Cho, MD
Generalized Myasthenia Gravis, gMG
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
- Trial name
- NCT05644561
- Testing
- Ravulizumab
- Where
- 11 sites in United States, Italy and 3 more
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pediatric Oncology
Fit to Fight Childhood Cancer
The aim of the study is to investigate the influence of exercise on physical performance and psychosocial aspects in children and adolescents with cancer during and after treatment.
- Trial name
- Kolibri (NCT05867186)
- Testing
- Exercise training
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
Soft Tissue, Lymphoma
Pediatric PET/MR Image Registry
The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in…
- Conditions
- Soft Tissue, Lymphoma, Osteosarcoma
- Trial name
- NCT03458520
- Testing
- PET/MR imaging, MR imaging, PET/CT imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Brain Tumor, Brain Tumor, Recurrent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease.
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric
- Trial name
- NCT04023669
- Testing
- Prexasertib, Cyclophosphamide, Gemcitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Brain Tumors
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.
- Trial name
- NCT07158710
- Testing
- HSK42360
- Where
- 6 sites in China
- Volunteers
- 159 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Low-grade Glioma
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
The purpose of this study is to investigate whether weekly Vinorelbine treatment can shrink or slow the growth of pediatric low-grade gliomas that have either returned or are continuing to grow.
- Trial name
- NCT01497860
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Eugene Hwang
Hematologic Malignancies, Nonmalignant Diseases
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609827
- Testing
- Melphalan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia, Relapsed Adult AML
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.
- Conditions
- Acute Myeloid Leukemia, Relapsed Adult AML, Relapsed Pediatric AML
- Trial name
- NCT03245424
- Testing
- ivosidenib (AG-120)
- Sponsor
- Agios Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.